Pashtoon M. Kasi, MD, MS

Articles by Pashtoon M. Kasi, MD, MS

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 27th 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

Trastuzumab Deruxtecan in HER2+ mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

First-Line Treatment Options for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 20th 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

Challenges With Molecular Testing in Metastatic Colorectal Cancer

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

Circulating Tumor DNA to Guide Treatment Selection for mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 16th 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

ByKristen Ciombor, MD, MSCI,Joleen M. Hubbard, MD,Joel R. Hecht, MD,Pashtoon M. Kasi, MD, MS,Kanwal Raghav, MD

February 9th 2023

Shared insight on the value tissue and circulating tumor DNA respectively provide in molecular testing for patients with metastatic colorectal cancer.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

ByPashtoon M. Kasi, MD, MS

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Kasi on the Role of MRD Testing in CRC

ByPashtoon M. Kasi, MD, MS

October 28th 2020

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Dr. Kasi on Utility of Personalized Medicine in Colorectal Cancer

ByPashtoon M. Kasi, MD, MS

January 21st 2020

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Pashtoon M. Kasi, MD, MS

Articles by Pashtoon M. Kasi, MD, MS

HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates

Trastuzumab Deruxtecan in HER2+ mCRC

First-Line Treatment Options for mCRC

Challenges With Molecular Testing in Metastatic Colorectal Cancer

Circulating Tumor DNA to Guide Treatment Selection for mCRC

Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

Dr. Kasi on the Role of MRD Testing in CRC

Dr. Kasi on Utility of Personalized Medicine in Colorectal Cancer

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies